Therefore, considering that overcoming mechanisms by which tumor cells resist chemotherapies could improve the survival rate of CRC patients, the current research was designed to explore the in vitro effects of CD44 silencing using specific siRNAs, as a targeted therapy strategy, combined with 5-FU drug on human CRC cells. The gene discussed is CD44; the disease is colorectal carcinoma.